Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients

Summary

The goal of this clinical trial is to determine whether oral supplementation with different nicotinamide adenine dinucleotide (NAD) precursors can improve visual function in adults with primary open-angle glaucoma. The main questions it aims to answer are:

1. Does daily oral administration of equimolar doses of nicotinamide riboside (NR), nicotinamide (NAM), nicotinamide mononucleotide (NMN), or nicotinic acid (NA) improve visual field sensitivity in glaucoma patients over the short term?
2. How do plasma NAD+ metabolite profiles change after administration of each precursor, and do these changes relate to improvements in visual function?

Researchers will compare NR, NAM, NMN, NA, and placebo groups to see if any of the NAD precursors lead to greater improvements in visual field sensitivity or changes in blood NAD+ metabolite levels compared to placebo.

Participants will:

Be randomly assigned to receive one of the four NAD precursors or placebo daily for two weeks.

Undergo comprehensive eye examinations, including visual field testing and optical coherence tomography, at baseline and after two weeks.

Provide blood samples before and after the intervention for measurement of NAD+ metabolites.

Have safety monitored through clinical examination.

This study will help identify whether boosting NAD+ levels with specific precursors offers functional benefit in glaucoma, and which blood metabolites may mediate these effects.

Conditions

• Glaucoma

Interventions

DIETARY_SUPPLEMENT

Nicotinamide Riboside

Oral supplementation of 300mg Nicotinamide Riboside (NR) daily for 2 weeks

DIETARY_SUPPLEMENT

Nicotinamide

Oral supplementation of 125mg Nicotinamide/Niacinamide (NAM) daily for 2 weeks

DIETARY_SUPPLEMENT

Nicotinamide Mononucleotide

Oral supplementation of 350mg Nicotinamide Mononucleotide (NMN) daily for 2 weeks

DIETARY_SUPPLEMENT

Nicotinic Acid

Oral supplementation of 350mg Nicotinic Acid (NA) daily for 2 weeks

OTHER

Placebo (Corn Starch)

Oral supplementation of 300mg Placebo daily for 2 weeks

OTHER

Placebo (Corn Starch)

Oral supplementation of 300mg Placebo daily for 2 weeks

Sponsors & Collaborators

• Christopher Kai Shun Leung

  lead OTHER

Principal Investigators

• Christopher Kai-shun LEUNG, MD · The University of Hong Kong

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-05-19

Primary Completion

2025-12-31

Completion

2026-12-31

Countries

• Hong Kong

Study Locations